NCT00369317 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 205
- units
- Participants
- groups
- description
- INDUCTION THERAPY COURSE I: Patients receive cytarabine IT on day 1 and cytarabine IV continuously over 96 hours, daunorubicin hydrochloride IV continuously, and oral thioguanine BID on days 1-4. COURSE II: Patients receive high-dose cytarabine IV over 3 hours BID on days 1, 2, 8, and 9 and asparaginase (IM) on days 2 and 9. COURSE III: Patients receive treatment as in course I. COURSE IV: Patients receive cytarabine IV, daunorubicin hydrochloride IV, and oral thioguanine as in course I INTENSIFICATION THERAPY: Patients receive cytarabine IV continuously over 168 hours on days 1-7 and etoposide IV over 1 hour on days 1-3. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. asparaginase: Given IM daunorubicin hydrochloride: Given IV cytarabine: Given IV or IT thioguanine: Given orally etoposide: Given IV laboratory biomarker analysis: Correlative studies
- id
- BG000
- title
- Treatment (Combination Chemotherapy)
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 265.73
- value
- 616.41
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- days
- classes
- categories
- measurements
- group Id
- BG000
- value
- 205
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 0
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 0
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 106
- title
- Female
- measurements
- group Id
- BG000
- value
- 99
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 12
- title
- Asian
- measurements
- group Id
- BG000
- value
- 2
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 28
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 141
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 22
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 48
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 154
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 3
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 187
- title
- United States
- categories
- measurements
- group Id
- BG000
- value
- 11
- title
- Canada
- categories
- measurements
- group Id
- BG000
- value
- 7
- title
- Australia
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 205
- units
- Participants
- groups
- description
- INDUCTION THERAPY COURSE I: Patients receive cytarabine IT on day 1 and cytarabine IV continuously over 96 hours, daunorubicin hydrochloride IV continuously, and oral thioguanine BID on days 1-4. COURSE II: Patients receive high-dose cytarabine IV over 3 hours BID on days 1, 2, 8, and 9 and asparaginase (IM) on days 2 and 9. COURSE III: Patients receive treatment as in course I. COURSE IV: Patients receive cytarabine IV, daunorubicin hydrochloride IV, and oral thioguanine as in course I INTENSIFICATION THERAPY: Patients receive cytarabine IV continuously over 168 hours on days 1-7 and etoposide IV over 1 hour on days 1-3. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. asparaginase: Given IM daunorubicin hydrochloride: Given IV cytarabine: Given IV or IT thioguanine: Given orally etoposide: Given IV laboratory biomarker analysis: Correlative studies
- id
- BG000
- title
- Treatment (Combination Chemotherapy)
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 265.73
- value
- 616.41
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- days
- classes
- categories
- measurements
- group Id
- BG000
- value
- 205
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 0
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 0
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 106
- title
- Female
- measurements
- group Id
- BG000
- value
- 99
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 12
- title
- Asian
- measurements
- group Id
- BG000
- value
- 2
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 28
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 141
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 22
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 48
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 154
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 3
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 187
- title
- United States
- categories
- measurements
- group Id
- BG000
- value
- 11
- title
- Canada
- categories
- measurements
- group Id
- BG000
- value
- 7
- title
- Australia
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle